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Abstract 
 
Basal Cell Carcinoma (BCC) is a common malignant tumor in Caucasians and accounts 
for 95% of non-melanoma skin cancers in the United States. BCC is primarily caused by 
UV radiation and is slow growing, although if left untreated, has high potential for spread 
to surrounding tissues.  Non-surgical treatment of superficial BCC involves the use of 
AldaraTM cream containing 5% w/w imiquimod as the active ingredient. Imiquimod 
(AldaraTM), a Toll-like receptor (TLR) agonist, is an immune response modifier with 
potent indirect antiviral activity. The topical delivery of imiquimod is desired over oral 
administration to eliminate the first-pass metabolism of drug in the liver while maximizing 
the drug concentration at the affected area.  However, cream dosage form suffers from 
the disadvantages such as dose variability, poor drug availability due to incomplete 
release of the drug and poor patient compliance.  We hypothesized that the sustained 
release of a therapeutic dose of imiquimod from the film would result in an effective 
treatment, while eliminating the need for daily cream application and the dosing 
variations associated with it. In order to test this hypothesis, imiquimod containing 
chitosan films were manufactured to achieve the desired controlled delivery of imiquimod 
and characterized for drug physical form, drug loading, content uniformity, and release 
behavior. In addition, effect of varying concentrations of Imiquimod and molecular weight 
of chitosan was studied on the release characteristics of the film.  In-house HPLC 
method was developed to analyze the drug concentrations during the release studies. 
The X-ray diffraction (XRD) data and content uniformity studies demonstrated the 
uniform imiquimod loading with no change in the physical form of the API within the 
chitosan film matrix. In conclusion, chitosan films containing 625 µg/cm2 imiquimod were 
developed with desired rate and extent of delivery of Imiquimod for single use weekly.  
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Chapter 1: Background 
Introduction 
Innate immunity plays a major role in the recognition of pathogen-associated molecular 
patterns. Through pattern-recognition receptors, foreign pathogens and tumor cells can 
be eliminated by direct killing as well as by indirectly activating the adaptive immune 
system. In the treatment of basal cell carcinoma (BCC), the drug, Imiquimod, acts as a 
Toll-like receptor (TLR) agonist and thereby stimulates the immune system. The overall 
objective of this research project was to develop a topical delivery system for imiquimod 
that would be safe and effective for the treatment of BCC.  An In-house HPLC assay for 
imiquimod was developed, and thereafter, imiquimod was loaded into chitosan films, and 
the rate and extent of release were evaluated. This introduction provides the background 
of BCC and its treatment by imiquimod. In addition, the rationale for the use of a 
chitosan film formulation is also discussed, which includes a summary of the properties 
and release characteristics of chitosan.  The section concludes with a statement of the 
problem and the general experimental approach. 
 
Basal Cell Carcinoma (BCC) 
BCC is a common malignant tumor in Caucasians and accounts for 95% of non-
melanoma skin cancers in the United States with approximately 4 million cases 
diagnosed each year. 1 The mortality associated with BCC is relatively low due to low 
incidence of cancer metastasis. However due to its high incidence, it remains a 
significant health concern. This is especially so as it can be disfiguring with adverse 
psychological consequences. 
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Exposure to ultraviolet radiation is a significant risk factor due to the induced 
DNA damage that in turn causes complex interactions among genes. 1 This also 
explains the susceptibility of Caucasians to this disease, who, have minimal protective 
pigmentation in the skin.  BCC occurs at various anatomical locations but most 
commonly is found in the head and the neck along with the trunk, which typically receive 
the greatest exposure to UV radiation.  It is slow growing, although if left untreated, there 
is high potential for spread to surrounding tissues.  This can lead to adverse events in 
the affected organs, which may be very debilitating, if the eyes or nose are involved. 2   
 
Treatment for BCC involves surgery or non-surgical approaches. Surgical 
procedures include electrodessication and curettage (ED &C), surgical excision and 
Mohs surgery, while non-surgical approaches include radiation and systemic or topical 
drug therapy. 3 Although, surgery remains the most common treatment modality, 
radiation and drug therapy have important roles in containing BCC. 
 
Imiquimod (AldaraTM) is an imidazoquinoline amine analog related to guanosine 
that acts as an immune response modifier with potent indirect antiviral activity. It is a 
prescription medication for the treatment of BCC, genital warts as well as actinic 
keratosis. 4 This and related molecules directly activate the innate immune system, 
resulting in cytokine release and costimulatory molecular expression followed by T-cell 
activation. It possesses antiviral and antitumor properties due to its ability to induce 
production of various cytokines that enhance both the innate and acquired arms of the 
immune system. 5 
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Imiquimod and its use in BCC  
 
 
Figure 1: Chemical structure of Imiquimod 
 
The relatively small size (Mw =240.3, pKa 5.4) and hydrophobicity coupled with a 
disease state located in the skin make imiquimod an ideal candidate for a topical drug 
delivery system. 6  Not surprisingly, good epidermal barrier penetration has been 
observed with topical application, e.g. the treatment of skin tumors. In several controlled 
clinical studies, imiquimod was shown to be effective for a variety of primary skin 
cancers and cutaneous metastasis of some malignancies.  
 
The exact mechanism of action of imiquimod is yet to be fully described, but it is 
clear that both major divisions of the immune system are involved. Mounting a robust 
immune response is crucial for an effective antiviral response in diseases, such as 
Human papillomavirus (HPV). Imiquimod, on the other hand, does not have direct 
antiviral properties, but rather it induces immune reactions leading to cytokine synthesis 
and secretion. 5 The release of cytokines includes Interferon-α (IFN- α), interleukin (IL-6), 
and tumor necrosis factor (TNF-α). 7 The immune response is dependent on the 
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recognition of foreign antigens presented by antigen-presenting cells (APCs), such as 
dendritic cells (DCs), Langerhans cells (LCs), macrophages and B lymphocytes that are 
activated by imidazoquinoline amines. The induction of cytokines stimulates the Th-1 
pathway while inhibiting the Th-2 pathway via stimulation of monocytes and DCs.  This 
results in the production of TNF-α. 7 These pathways also activate CD8 cells that 
become cytotoxic T cells against tumor cells and also provide the immune memory 
required for future protection. 8 In addition, imiquimod also induces epidermal LCs to 
mature into APCs thereby facilitating the development of true T-cell mediated immunity. 9 
These LCs, when activated, have increased mobility to promote migration to draining 
lymph nodes where they present antigen to T lymphocytes for inducing immunity. 10 
 
One of the major biological effects of imiquimod includes agonistic activity 
towards toll-like receptors (TLR) 7, and consecutively, the activation of nuclear factor-
kappa B (NF-κB). The TLR family of receptors has a critical role in pathogen recognition 
and activation of innate immunity. 11 The innate immune system is dependent on the 
detection of pathogens by phagocytic cells, either through complete fixation or by 
binding to specific receptors, to activate the natural killer (NK) cells. Imiquimod 
stimulates the immune system through its TLR-7 agonist activity, thereby increasing the 
NK cell activity and inducing proliferation and differentiation of B lymphocytes. 12 The 
overall effect of Imiquimod-induced TLR-7 mediated cytokine production is a strong 
activation and migration of cytotoxic T cells that release perforin to destroy tumor cells. 13 
Some studies have also shown that at high concentrations, Imiquimod may also exert 
direct pro-apoptotic activity in cultured tumor cells. 14 A schematic diagram of the 
biological pathways associated with the TLR agonist activity of imiquimod is depicted in 
Figure 2. 
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Figure 2: Schematic of the biological pathways associated with the TLR agonist activity 
of imiquimod (Referenced from reference 12) 
 
 
Imiquimod is currently used in the case of superficial BCC or as a postoperative 
intervention (adjuvant therapy).  Topical formulations, such as imiquimod (5% Aldara 
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cream), are very effective and has been approved by the FDA for treatment of superficial 
BCC as well as number of other diseases. 15 With topical application, it acts locally in the 
epidermis to enhance the Th1 response by activating the natural killer cells and 
stimulating B lymphocytes. 15  
 
AldaraTM cream is available in single 250 mg sachets that contain 12.5 mg of 
imiquimod.16 The patient information leaflet dictates that the user is to apply a thin layer 
of cream over a treatment area of not more than about 20 cm2. 17 It is also 
recommended that the cream be applied five to six times a week for six weeks and left 
undisturbed for 6 to 10 hours at the treatment site. 17 The cream is supplied on an 
outpatient basis with the intent that the patient applies the medication at home on the 
affected areas of the skin. Despite manufacturer’s recommended dosage, the amount of 
cream actually applied per unit area of skin as a 250 mg sachet can be expected to 
depend on the patient, and studies have indicated that it may be inappropriately spread 
over a much larger area of 386 cm2. 18 Hence, there is a potential for significant 
variability in the dose of imiquimod with self-administration that would lead to 
inconsistencies in the clinical response. In light of the pharmacology and the current 
shortcomings of the cream, it follows that a continuous delivery system, which adheres 
specifically to the cancerous site and provides occlusion against water and fluids, would 
provide a significant advantage. 
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Chitosan 
 
Topical delivery possesses a distinct alternative to oral delivery as the first-pass 
metabolism of drug in the liver is avoided.  In comparison to injectable products, there is 
no painful administration with needles in delivering a therapeutically effective amount of 
drug across the skin. 19 Perhaps of greatest significance is that there is local delivery of 
drug at the site of application.  This provides an enormous pharmacokinetic advantage 
for localized skin diseases, where the concentration of the affected region of the body is 
maximized and the concentration to the rest of the body, and thereby systemic side 
effects, is minimized.   
 
A polymer based topical patch/film would have significant advantages over the 
currently available cream formulation such as AldaraTM.  That is, the dose can be strictly 
controlled by the manufactured film, which will necessarily have a fixed dose that is 
delivered at a reproducible rate.  The area of coverage can also be limited, provided the 
film is formulated to allow cutting to a size and shape that matches that of the affected 
area of the skin. In addition, these films can be manufactured with the impermeable 
backing membrane that provides barrier against water and body fluids and hence 
enhanced patient compliance.  
 
In topical delivery systems, the polymer is the most important, non-active 
component. It determines the release characteristics of the drug as well as adhesion to 
the skin. 20 Both naturally occurring and synthetic polymers have been used for drug 
delivery to the skin.  Natural polymers have specific properties that are not easily altered, 
which may pose difficulties in meeting the requirements for transdermal drug delivery.  In 
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contrast, synthetic polymers can be synthesized with a wide range of properties but tend 
to have poorer biocompatibility. 19 In particular, skin irritation is common with currently 
available polymeric drug delivery systems.   
 
During the past three decades, several polymeric systems for topical delivery 
have been explored in the field.  Among the various polymer choices for film 
formulations, Chitosan, a natural polymer, is recognized as having many properties 
amenable for the delivery of imiquimod.  Chitosan is naturally occurring biopolymer 
derived from Chitin, which is one of the most abundant, renewable natural cellulosic 
polymer. Chitosan is a polysaccharide composed of two subunits, D-glucosamine and N-
acetyl-D-glucosamine, that are linked together by a β-(1,4) glycosidic bond. 21 It is 
biocompatible, biodegradable, non-toxic and non-antigenic while possessing 
immunological activity. 22 Chitosan also possesses unique biological properties that 
include bactericidal, bioadhesion, anti-tumoral activities. There is also evidence that it 
promotes wound healing. 23, 24  
 
Due to these distinct properties, Chitosan is used in various pharmaceutical drug 
delivery systems. For processing, it has good solubility in organic acid solvents, allowing 
ready formation of films by solvent evaporation. Cast chitosan films have reasonable 
tensile properties, which can endure the stress exerted with physical movement in 
various anatomical locations in the body. 25, 26 Localized delivery of therapeutic drugs 
using biodegradable polymers can provide slow and controlled release over the desired 
period of time. Cross-linking of chitosan is an approach that has been used to control the 
swelling rate and thereby the release rate. 27, 28  In addition, the molecular weight of 
chitosan influences the drug release properties, where a high molecular weight 
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decreases the degradation rate of chitosan at the same degree of deacetylation. 29 In 
transdermal applications, Chitosan may enhance the percutaneous penetration of drug 
compounds by opening tight junctions in the epidermis and therefore may enhance the 
delivery rate of low molecular drugs. 30, 31 In this study, Chitosan was selected as the 
polymeric carrier of imiquimod for development of a topical drug delivery system for the 
treatment of BCC. 
 
Statement of the Problem and Research Objectives  
In order to address the above stated deficiencies of the cream formulations and to 
improve the therapeutic approach to the treatment of BCC, the aim of this project was to 
design, prepare and test imiquimod-loaded chitosan films.  For this aim, the 
physicochemical characteristics of the film were characterized to elucidate those aspects 
required in achieving controlled delivery of imiquimod. In consideration of the treatment 
of BCC, the imiquimod-loaded chitosan film should be of fixed dimensions, have robust 
content uniformity, and provide sustained release for the duration of one week. To 
undertake this aim, In-house HPLC analytical method was developed, which provided an 
easy and sensitive determination of imiquimod during physico-chemical and release 
studies of the chitosan films. 
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Chapter 2: Development of The In-House High Performance Liquid 
Chromatography (HPLC) Method for The Analysis of Imiquimod 
 
Introduction 
 
Analysis of any pharmaceutical dosage form involves the requirement of a simple, 
robust, easily and rapidly performed analytical method for quantifying the concentration 
of the active ingredient, free of interference from other excipients. The developed 
analytical method should also have sufficient precision, accuracy and reproducibility to 
meet FDA guidelines. 32 Drug delivery systems containing Imiquimod are the subject of 
scientific studies for its in vitro release and hence there is a need for a quick, easy and 
inexpensive analytical method for its quantification. Analytical reports involving the 
determination of imiquimod are relatively scarce due to its fairly recent introduction. The 
HPLC methods that have been successfully employed to quantify imiquimod present 
certain limitations, particularly when working with small volume samples of biological 
origin. 33 In order to overcome such challenges and easily determine the amount of 
imiquimod released from our film formulations, a simple and inexpensive in-house 
analytical HPLC method utilizing UV detection was developed. 
 
Acknowledgement  
The author would like to acknowledge Dr. Tanmoy Sadhukha for all his kind assistance 
in setting up the analytical method for the determination of Imiquimod. 
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Experimental  
Materials 
Imiquimod (≥98%, HPLC) was purchased from Sigma-Aldrich (St. Louis, Missouri, USA) 
Acetonitrile (ACN; Fisher Scientific, Hampton, New Hampshire, USA), Methanol (MeOH; 
Fisher Scientific, Hampton, New Hampshire, USA), and acetic acid (Sigma-Aldrich, St. 
Louis, Missouri, USA) were of HPLC grade. The water used in all experiments was 
purified using a Millipore filtration unit (Millipore, Bedford, USA). The HPLC used for 
quantifying imiquimod was a Shimadzu system that consisted of a LC-10AD pump and 
SPD-10A/10AV UV-vis detector and an autoinjector. A 100 mm Accucore C18 column 
with a mean particle size of 2.1 µm was used. 
 
Methods 
HPLC analysis of Imiquimod 
The mobile phase composition was a 78:22 (v/v) mixture of 10 mM ammonium acetate, 
adjusted to a pH of 4.0 with acetic acid, and acetonitrile. Ammonium acetate was filtered 
through a 0.22 µm nitrocellulose membrane filter and degassed for 5 minutes using a 
bath ultrasonicator. The mobile phase was pumped through the column at a flow rate of 
0.3 mL/min with a column temperature of 40°C. Prior to the first injection, the column 
was equilibrated for 45 minutes with mobile phase. The injection volume was 3 µL, and 
the total run time was set to 6 minutes. The eluent was monitored at a detection 
wavelength of 319 nm.  
 
Preparation of standards 
A stock solution of 1 mg/mL imiquimod was prepared by dissolving an appropriate 
amount of drug in a 1% acetic acid solution. This solution was then further diluted with 
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the acetic acid solution to prepare standard solutions ranging from 2 to 200 µg/mL. 
These solutions were then each diluted (1:10) in 10 mM Ammonium Acetate buffer at pH 
4.0 to produce calibration standards ranging from 0.1 to 20 µg/mL. The stock solutions 
were kept in sealed, amber glass vials and stored in a refrigerator at 4°C. 
 
 
Specificity and linearity 
The specificity of the HPLC method was determined by comparing the HPLC trace to 
that obtained with a blank (mobile phase) at the retention time of the imiquimod peak. 
Identification of imiquimod peak in the standard solution was confirmed by running 
different concentrations of imiquimod and recording the retention time.  Linearity of the 
method was evaluated using seven different concentrations. A 3 µL aliquot of each 
solution was injected in duplicate. 
 
Accuracy 
The accuracy of the method was determined by calculating the recovery in four samples 
containing different imiquimod concentrations in replicates of six. The mean, standard 
deviation and coefficient of variance (Cv) were calculated for each concentration. 
 
Instrumental precision 
The instrumental precision was evaluated by injecting six replicates of a standard 
solution containing 8 µg/mL imiquimod, and the relative standard deviation (RSD), 
retention time and area response of imiquimod was calculated. 
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Method reproducibility 
The reproducibility of the proposed method was evaluated by injecting duplicate aliquots 
of samples that had been stored 4 days at 4°C and comparing the results obtained from 
linear regression to those obtained with freshly prepared standards. 
 
Results 
 
In Figure 2.1, an overlay of the HPLC chromatogram following an injection of a blank 
and sample containing imiquimod is given.  It can be seen that there is no interference 
from blank sample at the retention time of imiquimod peak. This confirms the specificity 
of the method in the detection of imiquimod. 
 
Voltage (µV) 
 
Time (minutes) 
Figure 2.1: Overlay chromatogram of Imiquimod and blank sample 
2µg/mL Imiquimod peak 
retention time 2.3 mins 
Blank sample 
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A calibration curve was obtained by plotting the response area from the chromatogram 
as a function of imiquimod concentration. The correlation coefficient from the graph was 
0.9996. The standard curve of imiquimod is as shown in Figure 2.2. 
 
 
Figure 2.2: Linearity curve of Imiquimod 
The accuracy of the method was calculated with three different imiquimod 
concentrations (0.3, 4, and 8 µg/mL). The results are as given in Table 1, where at a 
concentration of 0.3 µg/mL, the accuracy was 98.3%, while at 4 µg/mL and 8 µg/mL, the 
accuracies were 98.5% and 97.4%, respectively. The percent relative standard deviation 
(%RSD) for five replicates of 0.3, 4 and 8 µg/mL was found to be 2.90%, 2.54% and 
1.81%, respectively. It was also observed that the accuracy was slightly lower at higher 
concentrations, so a lower limit of quantification (LLOQ) of 0.1µg/mL was applied. Thus, 
a high accuracy and low coefficient of variation was observed using this method.  
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Table 1: Accuracy results of Imiquimod 
0.3 µg/mL Imiquimod   4 µg/mL Imiquimod   8 µg/mL Imiquimod   
Recovered 
Amount 
(µg/mL) 
% 
Accuracy  
% 
RSD 
Recovered 
Amount 
(µg/mL) 
% 
Accuracy  
% 
RSD 
Recovered 
Amount 
(µg/mL) 
% 
Accuracy  
% 
RSD 
0.31 103.33 2.90 4.05 101.25 2.54 7.75 96.88 1.81 
0.3 100.00 3.95 98.75 7.77 97.13 
0.31 103.33 3.78 94.50 7.75 96.88 
0.29 96.67 3.93 98.25 7.94 99.25 
0.31 103.33 3.98 99.50 7.93 99.13 
 
The instrumental precision was determined by calculating the percent relative standard 
deviation for six replicates at a 0.6 µg/mL standard solution and was found to be 2.18% 
and 0.33% for area response and retention time, respectively. 
 
Discussion 
The development of this method evolved through the optimization of chromatographic 
parameters that involved testing several different mobile phase compositions. As an 
initial start point, Ammonium Acetate buffer (pH 4.0, 10mM): ACN 85:15 (v/v) mobile 
phase was used. This led to a run time of 12 minutes and resulted in peak broadening. 
The organic phase was increased to 20% (Ammonium Acetate:ACN ; 80:20) and that led 
to a shorter run time of 8 minutes, however  some peak tailing was observed. In order to 
obtain good peak symmetry and fast elution of imiquimod, an acidic pH of the mobile 
phase buffer was essential. The mobile phase composition that gave the best peak 
shape and optimal retention time was Ammonium Acetate buffer (pH 4.0, 10mM): ACN 
78:22 (v/v). Using this mobile phase, the imiquimod peak had a very short retention time 
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of 2.3 ± 0.1 minutes that was well displaced from the solvent front. The analysis of 
imiquimod was carried out at a detection wavelength of 319 nm, and the run time was 
set at 6 minutes. This method was successfully applied in the accurate determination of 
drug from our film samples due to the simplicity of the technique and the short analysis 
time.  
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Chapter 3: Development and characterization of Imiquimod films 
Introduction  
 
Topical delivery of imiquimod in the treatment of BCC is a very efficient non-
surgical procedure with maximum restoration of affected skin. As discussed in chapter 1, 
chitosan has recognized applications in tissue engineering, wound dressing and drug 
delivery and thus is an excellent candidate for the polymer in a polymeric film system.  
For this application, an analysis of the drug delivery of the currently available cream 
provides useful information to guide the development of film.  In essence, the rate and 
extent of drug delivery to the skin from the film should be equivalent to that provided by 
the cream, taking into account the multiple dosing of the cream compared with the once-
a-week application of the film.   
 
AldaraTM cream contains 5% imiquimod in single 250 mg sachets, which is 
equivalent 12.5 mg of imiquimod. 16,17 Studies have shown that only about 11.5% or 1.44 
mg imiquimod is released. 34 The cream is applied as a thin layer over an area not more 
than about 20 cm2, which translates to a mass delivery of 0.072 mg/cm2.   Finally, the 
cream is applied five to six times per week or equivalently, the cream is applied every 26 
to 33 hrs. 17 Taking the midpoint as 30 hrs, the flux of drug from the cream is 0.0012 
mg/cm2/hr.  This value represents the target transport rate that provides the necessary 
guidance in evaluating the release characteristics of the film.  As the desired duration is 
one week or 168 hr, the minimum total mass required in the film would be 0.2 mg/cm2 or 
200 μg/cm2. 
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In the following, films were formulated with imiquimod, and the release rates 
were characterized. Specific parameters were examined, which included the release 
media, cross-linker concentration, molecular weight of the chitosan, and imiquimod 
concentration in the films. 
 
Acknowledgement 
The author would like to express sincere gratitude and acknowledge Dr. Buddhadev 
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Experimental 
Materials 
Chitosan, of two molecular weights, were obtained from SigmaAldrich (St. Louis, MO, 
USA). Medium molecular weight chitosan (MMWC) has a molecular weight of 190-310 
kDa, deacetylation degree of 75-85%, and a viscosity of 200-800 cPs. Practical grade 
chitosan (PGC) has a molecular weight of 190-375 kDa, deacetylation degree ≥75%, 
and a viscosity >200 cPs. Dulbecco's phosphate buffered saline (DPBS), and 
Dulbecco’s Modified Eagle Medium (DMEM) were purchased from Invitrogen 
Corporation (Carlsbad, CA, USA). Propylene Glycol was purchased from Sigma-Aldrich 
Corp. (St. Louis, Missouri, USA) and Captisol was purchased from Cydex 
Pharmaceuticals (Lawrence, Kansas, USA) 
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Methods 
 
Solubility determination of imiquimod  
The solubility was determined by placing about 1 mg, weighed accurately, of imiquimod 
in a glass vial along with 1 mL of DPBS or DMEM containing a range of concentrations 
of captisol up to 10%. The vials were placed on an oscillating mixer set at 400 rpm held 
at room temperature.  After 24 hrs, the vials were centrifuged at 10,000 rpm for 10 
minutes, and about 800 µL aliquot was drawn through a 0.45 µm syringe filter.  The 
filtrate was then analyzed for imiquimod concentrations by injecting 3 µL on the HPLC. 
For this experiment, a single sample was taken at each time point. 
 
Preparation and characterization of imiquimod-loaded chitosan films 
 
For film preparation, a 40 mL solution was prepared containing 1.5% (w/v) medium 
molecular weight chitosan, 0.5% (v/v) acetic acid and 12.31 mg of Imiquimod. With this 
solution, 36mL was added to an 85 mm glass culture disc and then dried for 24 hours at 
40°C in a convection oven. Separate studies were conducted with different amount of 
chitosan and inclusion of 5% (v/v) Propylene Glycol.  
 
The film thickness was measured by using a Marathon electronic digital micrometer 
(Marathon, Hong Kong) at five selected regions in the ¼” sections of four different cast 
films.  The caliper was adjusted to the point when resistance to turning was encountered 
with the film.  The crystallinity of the film was assessed by X-ray diffraction. 
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Content uniformity of Imiquimod in the films 
 
To determine the uniformity of imiquimod in the film, six different Imiquimod film sections 
of 0.6 cm were cut out and were incubated with 1% (v/v) acetic acid solution for two 
hours followed by centrifugation. The resulting solution was filtered and analyzed for 
Imiquimod content using HPLC.  
 
In vitro release measurement  
 
The amount of Imiquimod released as a function of time was determined as follows.  
From the cast films, circular discs were punched out using a 1/4" single hole punch, 
which had a diameter of 0.63 cm (area was 0.3 cm2).   Each disc was placed in a 20 ml 
glass scintillation vial with 10 mL of medium.  Two different media were used; 100 mM 
sodium acetate at pH 3.7 and DPBS at pH 7.4.  The vials were placed into a 
thermostatted (32 °C) shaker and oscillated at 100 rpm.   At 0.5, 1, 2, 4, 6, and 24 hrs, a 
1 ml aliquot was taken and immediately replaced with 1 mL media.  The sample was 
placed in a sealed test tube and stored in the refrigerator until assayed by HPLC.  The 
experiment was carried out in quadruplets. From the assayed concentration and volume 
of the aliquot, the mass in each sample was calculated.  After correcting for the 
“sampling with replacement,” the cumulative mass released was expressed as a function 
of time.   
 
 
 
   21 
 
Effect of chitosan grade on in vitro release of imiquimod  
 
Films containing imiquimod were prepared using two different molecular weights 
(medium molecular weight and practical grade) of chitosan along with 5% PG.  For each 
formulation, 0.6 cm circular disc (area = 0.3 cm2), containing 43.4µg of imiquimod, was 
cut out and placed in a scintillation vial with 10 mL of DMEM containing 10% FBS. The 
release temperature was maintained constant at 32 °C.  The time points were 0.5, 1, 2, 
4, 6, and 24 hrs.  At each time point, 1 mL of the release media was withdrawn and 
replaced with 1mL of fresh DMEM supplemented with 10% FBS.  The collected release 
media was analyzed using HPLC for imiquimod concentration.  The cumulative release 
percent of imiquimod as a function of time was plotted 
 
Effect of Imiquimod content on release  
 
For this purpose, imiquimod films containing 10 µM (8.56 µg/cm2 film), 50 µM (42.79 
µg/cm2 film), and 100 µM (85.57 µg/cm2 film) were prepared using 1.5 % (w/v) medium 
molecular weight chitosan with 5% PG.  0.6 cm circular discs (area = 0.3 cm2) were cut 
out from each of the different films and placed in a scintillation vial with 10 mL of DMEM 
containing 10% FBS. The release temperature was maintained constant at 32 °C.  Sink 
conditions were maintained for all films during the release study.  
 
Results  
The results from the solubility measurements of imiquimod in DPBS and DMEM as a 
function of captisol concentration are given in Figures 3.1 and 3.2.  For DPBS, the 
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solubility in the absence of captisol was 1.5 µg/mL (Figure 3.1A). The aqueous solubility 
is reported to be about 2 µg/mL. 34 With the addition of captisol, the amount of imiquimod 
in solution increased in a linear manner reaching a concentration of 21 µg/mL at the 
highest captisol concentration of 10%.   The best fit intercept and slope using linear 
regression were 1.00 µmol and 0.9 (µmol imiquimod/µmol captisol) in DPBS and DMEM, 
respectively. 
In Figure 3.1B, the corresponding results plotted in moles are given.  Captisol is a β-
cyclodextrin derivative containing seven glucose units and has a cavity size of 0.7 nm.  
Imiquimod has a hydrophobic benzene ring that is sufficiently small to reside within this 
cavity.  However, the best fit slope of the graph was only 0.0017 indicating that almost 
600 captisol molecules were needed to solubilize each imiquimod molecule.  Thus, while 
association may involve insertion of the ring into the cavity, it is apparent that the 
attractive energy is weak.  As such, captisol is a poor solubilizer of imiquimod.   
 
Figure 3.1: Imiquimod solubility (A) Amount of imiquimod in Dulbecco's 
phosphate buffered saline (DPBS) as a function of captisol concentration on a 
mass basis, (B) Moles of imiquimod in solution as a function of moles of captisol 
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In the presence of DMEM media, the solubility of imiquimod was about 9.5 
µg/mL. As with DPBS, the addition of captisol increased the amount of imiquimod in 
solution.  Specifically, the observed concentration was 25 µg/mL in presence of 5% 
captisol and 30 µg/mL with 10% captisol in DMEM (Figure 3.2A).  However, in contrast 
to DPBS, the amount of imiquimod in solution was more variable and may have not 
increased linearly with the captisol concentration.   
 
Discounting the possibility of nonlinearity and applying linear regression, the resulting 
best-fit slope with DMEM was 0.0017 mol/mol.  This value is equivalent to that observed 
with captisol in DPBS.  This indicates the solubilizing effect of captisol is 
indistinguishable in the two different buffer solutions, where comparable moles 
solubilized per mole of captisol were found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Imiquimod solubility (A) Amount of imiquimod in DMEM in presence of 
captisol, (B) mole ratio of imiquimod to captisol  
 
The solubilities of imiquimod in DPBS and DMEM were 1.5 and 9.5 µg/mL, 
respectively.  The much higher solubility observed with DMEM is likely due to the 
B 
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presence of plasma proteins in the media. From pharmacokinetic studies reported in the 
product literature, Imiquimod is about 90-95 % bound to proteins. 34 This binding would 
increase the total amount of drug in solution.  With the assumption that the solubility of 
free imiquimod remains unchanged in the presence of proteins, then 1.5 µg/mL of 
imiquimod is free, and the remaining 8.0 µg/mL is bound or about 84%.  This is in 
reasonable agreement with the literature value reported above.  Moreover, if the 
extrapolated value of DMEM from linear regression is used, the solubility value obtained 
would be 13.8 µg/mL and therefore the percent bound would be about 90%.   
 
In Figure 3.3, a photograph of the Imiquimod loaded chitosan film is given.  The film 
appears as a homogeneous, translucent circular disk.    
 
 
Figure 3.3: Photograph of imiquimod loaded chitosan film 
 
 In Figure 3.4, the powder x-ray patterns of Imiquimod, chitosan, and Imiquimod 
loaded chitosan film are given.  Crystalline imiquimod has characteristic peaks with 2θ 
values of 11, 15, 19, 22 and 24°, consistent with the literature. 35 In contrast; chitosan 
has a broad peak centered near 20°.  With incorporation of imiquimod into chitosan, the 
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characteristic peaks of imiquimod are visible and are seen to arise from a broad halo, 
which appears centered near 22°.  These features are consistent with crystalline 
imiquimod being present in the film composed of an amorphous polymer.  It is known 
that as the particle size decreases, there are fewer diffraction planes compared larger 
particles. With fewer planes, a reduction in peak intensity as well as broadening of the 
peak can be observed. It is noteworthy that the peaks arising from imiquimod, when 
present in the film, do not appear to be visibly broadened suggesting a relatively large 
particle size. 
 
Figure 3.4: Powder x-ray diffraction patterns of Imiquimod, chitosan, and 
Imiquimod loaded chitosan film. 
 
The results from measurement of the film thickness are as given in Table 3.1. 
The average thickness of the sections for the four different films was 0.101 mm. For the 
20 measurements, the thickness ranged from 0.095 to 0.103 mm.  The mean values for 
the four different films ranged from 0.100 to 0.102 mm, reflecting the excellent 
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reproducibility of the preparation method.  There appears to be more variability in the 
thickness of a given film than in the variability between films, which is a consequence of 
the limitation of the measurement technique by electronic caliper. The edge of the film 
was thicker due to wetting of the side of the dish by the solution. However, circular 
punches were taken from the middle portions of the film, and the edges were avoided to 
yield homogeneously flat films. The mass of the 0.3 cm2 film circle was measured to be 
2.88 mg. Therefore, the density was estimated to be (2.88mg/(0.0101 cm)(0.3 cm2) = 
0.960 g/cm3. 
 
Table 3.1: Measured thickness at five locations (R1-R5) for four different 
imiquimod/chitosan films.   
                                   Thickness (mm)     
  R-1 R-2 R-3 R-4 R-5 Average SD CV (%) 
Sample 1 0.103 0.105 0.095 0.102 0.103 0.102 0.004 3.79 
Sample 2 0.1 0.099 0.102 0.101 0.099 0.100 0.001 1.30 
Sample 3 0.103 0.101 0.1 0.101 0.1 0.101 0.001 1.21 
Sample 4 0.099 0.101 0.101 0.103 0.102 0.101 0.001 1.47 
 
The results of assessment of the content uniformity of imiquimod are as given in 
Table 3.2. Here, the amount of imiquimod determined in six different films is given along 
with the mean, standard deviation and associated coefficient of variation (CV).  The 
average amount of imiquimod was found to be 43.36 µg with a CV of 1.76%. 
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Table 3.2: Amount of imiquimod assayed in six different films, mean, standard 
deviation and coefficient of variance.   
Sample Imiquimod amount. (µg) Average (µg) SD CV (%) 
Sample-1 43.11       
Sample-2 44.11       
Sample-3 43.85 43.37 0.77 1.77 
Sample-4 43.66       
Sample-5 43.50       
Sample-6 41.96       
 
The effect of media pH on the in vitro release rate from imiquimod films was 
assessed. For this purpose, we used 1.5% (w/v) medium molecular weight chitosan 
(MMWC) films with imiquimod and performed the release in 100 mM sodium acetate 
buffer at pH 3.7 (Figure 3.5A) and also in DPBS at pH 7.4 (Figure 3.5B). From Figure 
3.5A, it is seen that at a pH of 3.7, there is an initial burst release of about 80% with 
100% release at the end of 2 hrs.  However, at biological pH of 7.4 (figure 3.5B), a burst 
release of only about 2% was observed.  The cumulative release increased nonlinearly, 
and at 100 min, the release rate was very low.  At 24 hrs, only 12 % was released 
corresponding to 5.21 µg.  Thus, much more rapid and complete release was observed 
at a pH of 3.7 relative to a pH of 7.4. 
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Figure 3.5: Effect of pH on in vitro release of imiquimod: (A) pH 3.7, & (B) pH 7.4  
 
This phenomenon could be attributed to the pH dependence of the amount of 
imiquimod in solution.  Imiquimod is a basic drug, and the general hypothesis is that the 
ionized form of a drug is infinitely soluble while the non-ionized form is soluble in a pH 
dependent manner. 36 Therefore, this relationship allows derivation of the following 
equation in determining the total amount of imiquimod in solution; where Cs is the 
solubility of the non-ionized form of the drug.  For a weak base: 
  
Ctot = Cs[1+ 10(pKa-pH)]  
The literature value for the pKa of Imiquimod is 5.4, the measured solubility above was 
1.5 µg/mL, and the pH of the solution was 3.7.  The total amount of imiquimod in solution 
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may be calculated as: 
  Ctot  =  Cs*[[1+ 10(5.4-3.7)] 
 Ctot = 76.7 µg/mL 
Thus, with the 50-fold increase in the concentration, there would be a correspondingly 
large increase in the rate of drug release.  
 
Figure 3.6: Effect of cross-linker concentration in film on imiquimod release using 
5% (w/v) chondroitin sulfate, 10% (w/v) chondroitin sulfate, & 20% (w/v) 
chondroitin sulfate 
 
The effect of cross-linker concentration on the release rate of imiquimod from the 
films was also assessed. For this purpose, we used 1.5 % (w/v) medium molecular 
weight chitosan (MMWC) with either 5% chondroitin sulfate, 10% chondroitin sulfate, or 
20% chondroitin sulfate as the cross-linking agent. The release pH was maintained at 6.  
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From the graphs (Figure 3.6), it is observed that in case of the 5% chondroitin sulfate 
cross-linked film, there was an initial burst release of about 45%. About 85% of the 
loaded imiquimod was released after 10 hours, followed by a very low release rate 
extending to 48 hours. The 10% chondroitin sulfate cross-linked film had a slightly higher 
burst of about 50%, proceeding to about 85% cumulative release in 10 hours similar to 
the 5% cross-linked film. It was observed that the presence of chondroitin reduced the 
burst effect and also had a modest effect to prolong the time for complete release.  The 
presence of higher cross-linking in the 20% chondroitin sulfate film had about half the 
burst effect as compared to the 10% chondroitin sulfate film, thereby depicting a more 
sustained release reaching completion in about 48 hours.  
 
The swelling ratio was estimated to be about 1.5 for 0.1 mm thick films at a pH of 
7.4.  In contrast, there was only a 2 % increase in film thickness with addition of 
chondroitin sulfate.  Chondroitin is a sulfated glycosaminoglycan, which can undergo 
complexation with the positively charged chitosan.  This may be expected to cause a 
reduction in the swelling.  However, the low pH is associated with limited swelling of 
chitosan and thus it would appear that addition of chondroitin did not induce a further 
contraction of the film, which would have been evident in a slower release profile.   
 
The cumulative imiquimod release as a function of time from the films prepared 
with medium molecular weight chitosan (MMWC) and practical grade chitosan (PGC) is 
as given in Figure 3.7. The release pH was maintained at about 7. With the MMWC, 
there was a burst release of 35 % followed by a nonlinear release profile, where the rate 
gradually slowed.  About 62% of the imiquimod was release at 150 min.  For the PGC, a 
similar profile was observed, although the burst release was larger, 26%, and the total 
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release was smaller, with about 60% released at 150 hrs.  These results indicate that the 
grade of chitosan failed to have any significant effect on the release of imiquimod.  In the 
interest of obtaining a higher release rate, the medium molecular weight chitosan was 
used in the final formulation. 
 
 
Figure 3.7. Cumulative imiquimod release as a function of time for films 
formulated with medium molecular weight chitosan (MMWC) and practical grade 
chitosan (PGC) 
The results from the effect of imiquimod content in the films on the release rate 
are as given in Figures 3.8. In this study, three different imiquimod films containing 8.57 
µg/cm2 film (equivalent to 10 µM imiquimod in each film section), 42.79 µg/cm2 film 
(equivalent to 500 µM imiquimod in each film section), and 85.57 µg/cm2 film (equivalent 
to 100 µM imiquimod in each film section) were used.  As seen in the graphs, the 10 µM 
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equivalent film section had a higher initial burst of 80%, nearing complete release in 
about 5 hours while both the 50 µM and 100 µM equivalent films had lower initial burst of 
65-70% proceeding to about 85% cumulative release.   
 
Figure 3.8: Cumulative imiquimod release as a function of time for films 
composed of 10µM equivalent Imiquimod per film section, 50 µM equivalent 
Imiquimod per film section, and 100µM equivalent Imiquimod per film section 
Discussion 
Conventional treatments available for skin cancers include surgery and radiation 
therapy, both of which are well established and widely applied. However, the potential of 
these approaches are limited and in some cases unsuitable for large or multiple lesions, 
which ultimately leads to poor cosmesis. 37 Other treatment modalities, such as 
curettage, and cryotherapy, are mostly effective against superficial BCC but are 
associated with a high rate of recurrence. 37, 38 The National Comprehensive Cancer 
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Network (NCCN) states that the goal of treatment for BCC is the elimination of the tumor 
with maximal preservation of function and physical appearance. Imiquimod has been 
increasingly used in the topical treatment of BCC with successful clinical outcomes while 
having no evidence of scarring. 39 Thus our chitosan film was formulated with imiquimod 
with the goal of controlled topical delivery to superficial BCC lesions. In consideration of 
the treatment of BCC, the imiquimod-loaded chitosan film should be of fixed dimensions, 
have robust content uniformity, and provide sustained release for the duration of one 
week. 
 
Imiquimod-loaded chitosan films were readily formed by solvent evaporation, 
which resulted in an aesthetically appealing film formulation.   Based on our results, the 
process resulted in very uniform, reproducible films with respect to thickness with a 
coefficient of variance (Cv) of less than 1.5%. The content uniformity was also very good 
in which 153.32 µg/cm2 imiquimod was obtained.  The findings from these 
characterization studies strongly suggested that our film composition contained a 
homogeneous dispersion of imiquimod into the hydrophilic chitosan, resulting in uniform 
thickness and content distribution across the film, which fulfills two of the criteria set for 
the film. In addition, the crystallinity of imiquimod inside the amorphous polymer was 
intact as characteristic diffraction peaks are seen in the powder X-ray diffraction pattern 
in Figure 3.4. This tends to favor chemical and physical stability of the formulation. 
 
The more challenging aspects of the project relate to modulating the properties of 
the film to delivery drug at the needed rate and duration for a once a week application.  
The solubility study was necessary to identify appropriate conditions for which the 
release measurements could be made under sink conditions.   We were able to 
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demonstrate that the use of sink conditions enabled a complete release within 6 hours 
for the films containing the smallest amount of imiquimod.  Our studies also indicated the 
importance of pH in the release rate, which perhaps could provide a means through 
which the rate of release can be modulated.   
 
Chitosan is a frequently used polymer due to its biocompatibility, biodegradability 
and non-toxicity. 22 Localized delivery of therapeutic drugs using chitosan are capable of 
slow and controlled release over the desired period of time and hence chitosan served 
as a desirable polymer in our film formulation for imiquimod delivery to BCC lesions. The 
release of biological agents from chitosan film is dependent on its swelling behavior, 
which is a function of the pH and is also controlled by the cross-linker.  Literature 
indicates that the degree of swelling is inversely proportional to the degree of cross-
linking. 25 The results from our release study revealed that the presence of crosslinking 
significantly reduced the rate compared to films without crosslinking, but no significant 
differences were evident when the cross-linker concentration was varied from 5 to 20% 
(Figure 3.6).  Based on this observation along with the fact that the films would likely 
remain intact, when adhered to the skin, no cross-linking agent was used in our final film 
formulation so as to reduce one excipient from the film. The release profile from all the 
three cross-linker concentration films showed a near-complete release within 48 hours 
when the release pH was maintained at 6. Propylene Glycol was introduced in order to 
mitigate the brittleness of the films in the absence of a cross-linker. 
 
Another important consideration of chitosan-based release is the effect of 
chitosan molecular weight on the drug release profile, where a high molecular weight is 
associated with low degradation of chitosan. 23 In order to examine this condition; we 
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incorporated both medium molecular weight (MMW) and high molecular weight practical 
grade chitosan (PGC) in our formulation and monitored the release. As observed, the 
release profiles obtained from the different molecular weight films were almost identical 
with a slightly higher initial burst in the case of the medium molecular weight chitosan 
film.  Thus, no correlation with molecular weight or grade of chitosan was found.  It is 
likely that degradation did not occur in the films used in this study, or if present, did not 
affect the release rate of the relatively low molecular weight, Imiquimod.  
 
Since, further studies would require in vitro evaluation of films on supporting the growth 
of cells where a neutral pH of 7 would be desired. The release pH was kept at 7 for our 
final film formulation since our release media (DMEM substituted with 10% fetal bovine 
serum) had the same pH and as a result the profile obtained had a longer release span 
as compared to the previous release studies of different cross-linked films. The different 
cross-linker concentration film release was performed at a pH of 6, which falls into the 
pH range of skin. However, the profile obtained from the films depicted a faster rate of 
release as compared to our final formulation due to chitosan’s higher solubility in lower 
pH. Thus, achieving a steady release over the course of six days, our final film 
formulation contained medium molecular weight chitosan as the polymer.  This may 
prove to be helpful should the film reach manufacturing, because specifications on 
molecular weight need not be narrow.  
 
Our bioadhesive, topical chitosan films were capable of releasing a defined dose of 
imiquimod over a period of six days. It should be noted that the maintenance of the 
cream in some anatomical locations of the human body would present difficulty due to 
factors such as moist environments and high shear forces. Previous studies have shown 
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that the Aldara 5% cream 250mg single sachet is capable of only releasing 11.5% of its 
imiquimod content. 40 The cream is applied five to six times per week, and as calculated 
before, the minimum total mass of imiquimod required in the film to obtain the required 
dosing would be 200 μg/cm2. Our films had an imiquimod content of 153 μg/cm2 with 
about 62% release over the course of six days.  While apparently low, such a film would 
represent a good starting point in clinical testing.   
Figure 3.9: Predicted (----) release trend of the amount of Imiquimod released per 
unit area against time from commercial films 
 
Figure 3.9 depicts the release profile from our final film formulation that is 
composed of 1.5% (w/w) medium molecular weight chitosan, where the release was 
measured in media composed of DMEM substituted with 10% fetal bovine serum.  The 
solid graph shows the amount of imiquimod released per unit area from both sides of our 
film, as would occur in the release studies.  Since, our proposed film would release its 
payload from only one side of the film, the dashed line represents the predicted release 
trend from one-side.  For this estimate, we assumed that the rate of release would be 
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decreased by a factor of two. Hence, in this case, about 32% imiquimod release is 
expected within the course of one week. Therefore, in order to achieve a similar release 
as compared to the AldaraTM cream, the required therapeutic dosing in the film should be 
about 625 μg/cm2 in order to obtain the desired flux of drug of 0.0012 mg/cm2/hr over the 
course of 168 hours.   
 
Our experimental findings also indicated that the variation of imiquimod loadings 
in the films across a range of 50 µM - 100 µM equivalent Imiquimod did not significantly 
affect the release pattern (Figure 3.8).  Thus, it seems likely that an imiquimod loaded 
film could be formulated as an external bioadhesive bandage and could be applied on 
the skin lesions for a week in order for a complete, therapeutic payload release. Overall, 
the films manufactured contain a defined drug loading per unit area and hence could be 
applied in accordance with the area of the lesion in order to achieve better clinical 
outcomes while mitigating administration variability. This could then be used in a clinical 
trial involving different skin neoplasia and therefore aid in the determination of an 
appropriate dose of imiquimod for successful treatment outcomes. 41 Therefore, the local 
controlled delivery of imiquimod from a mucoadhesive film deserves further attention as 
an effective non-invasive treatment modality. 42   
 
In summary, topical delivery of drugs continues to represent an attractive alternative to 
other delivery routes while offering advantages such as low systemic toxicity and 
localized delivery. 19  Future work in topical imiquimod delivery to BCC would involve 
further optimization of film formulation parameters, thus enabling more control of the 
drug release. In order to increase the bioavailability of the poorly soluble imiquimod, the 
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development of a system that could form films through spray drying would be of 
significant interest.  
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